Organization
19 Interestana reports mention Moderna, newest first. Each is summarised from the original reporting and links back to its publisher.
Cellular Intelligence, a company focused on developing AI models to predict and control cellular behavior for faster and cheaper drug development, announced significant additions to its scientific advisory board on Monday.
In April 2026, Atlassian appointed Avani Prabhakar as its chief people and AI enablement officer, expanding her oversight from a 700-person HR team to 3,500 employees responsible for AI transformation across the company's 14,000 staff.
Moderna's personalized cancer vaccine has demonstrated promising results in a recent clinical trial, offering a beacon of hope for individuals battling cancer. The trial's positive outcomes, published online on August 28, 2026, in Nature, underscore the potential of mRNA technology…
Corporate America is embracing artificial intelligence at a steady, albeit not breakneck, pace, according to a new analysis that counters both extreme hype and dismissal of AI's potential impact. While headlines often suggest an overnight transformation or outright overvaluation…
Moderna's personalized mRNA cancer vaccine has shown promising results in a clinical trial, successfully preventing the recurrence of melanoma in patients. The study, published online on August 20, 2026, in Nature, indicates that the vaccine could be a significant advancement…
Merck and Moderna announced on December 13, 2023, that their investigational mRNA cancer vaccine, in combination with Merck's immunotherapy Keytruda (pembrolizumab), demonstrated a statistically significant and clinically meaningful improvement in recurrence-free survival (RFS) for patients with stage III or IV…
Moderna is placing significant strategic emphasis on its messenger RNA (mRNA) technology, the same platform that underpinned its highly successful COVID-19 vaccines, to pioneer a new generation of cancer treatments.
Moderna and Merck announced on June 5, 2024, that their investigational mRNA-based cancer vaccine, Intisemran (mRNA-4157/V940), significantly reduced the risk of melanoma recurrence and spread in patients with high-risk stage III/IV melanoma.
Pharmaceutical companies Moderna and Merck announced on Wednesday that their experimental mRNA-based cancer vaccine, designed to target a patient's specific tumor mutations, demonstrated efficacy in a Phase 3 clinical trial for melanoma patients.
Moderna and Merck announced promising results from a late-stage clinical trial for a personalized mRNA vaccine designed to prevent the recurrence of melanoma, the deadliest form of skin cancer. The trial, which involved a substantial number of participants, demonstrated…
Moderna's experimental personalized cancer vaccine, mRNA-4157/V940, has demonstrated early encouraging results in a Phase 2b clinical trial, offering a potential new avenue for cancer treatment and a significant opportunity for the biotechnology company.
Moderna's messenger RNA (mRNA) influenza vaccine has received approval, marking a significant advancement in the fight against seasonal flu. This new vaccine technology offers the potential for manufacturers to respond more rapidly to the constantly changing strains of the influenza…
The U.S. Food and Drug Administration (FDA) has granted approval for Moderna's trivalent flu vaccine, designated as mRNA-1010 and marketed under the name mFLUSIVA, for use in individuals aged 50 years and older.
The U.S. Food and Drug Administration (FDA) has granted approval for Moderna's mRNA-based flu vaccine, designated as mRNA-1010 and also known as mFLUSIVA. This landmark decision, announced on Thursday, marks the first time an mRNA technology has been approved…
The U.S. Food and Drug Administration (FDA) has granted approval for mFlusiva, a novel influenza vaccine developed by Moderna, marking the first use of mRNA technology in a flu shot for adults aged 50 and older.
The U.S. Food and Drug Administration (FDA) has granted approval for mFlusiva, a novel flu vaccine developed by Moderna, marking the first time the mRNA technology central to the COVID-19 pandemic response has been applied to influenza immunization.
Moderna co-founder Kenneth Chien, reflecting on his 50-year scientific career, highlighted an Hermes belt gifted by Moderna CEO Stéphane Bancel in 2013. This gift followed Chien's instrumental role in securing a significant partnership between the nascent mRNA startup Moderna…
Independent advisors for the Food and Drug Administration voted 9-0 on Friday to recommend the approval of Moderna's seasonal mRNA flu vaccine, designated mRNA-1010 and branded as mFlusiva. This decision followed an attempt by a Trump appointee at the FDA…
A panel of advisers to the Food and Drug Administration endorsed Moderna's seasonal mRNA flu vaccine on Thursday, marking a significant step after the vaccine faced controversy earlier this year when a top agency official initially refused to review it.